History and Future of the Multidisciplinary Association for Psychedelic Studies (MAPS)

REFERENCES

• Adamson, S. 1985. Through the Gateway of the Heart: Accounts of Experiences with MDMA and Other Empathogenic Substances. San Francisco: Four Trees Publications.
   Google Scholar
• Bedi, G. & Redman, J. 2008. Ecstasy use and higher-level cognitive functions: Weak effects of ecstasy after control for potential confounds. Psychological Medicine 38 (9): 1319–30.
   PubMed Web of Science ®Google Scholar
• Bedi, G.; Van Dam, N.T. & Redman, J. 2010. Ecstasy (MDMA) and high prevalence psychiatric symptomatology: Somatic anxiety symptoms are associated with polydrug, not ecstasy, use. Journal of Psychopharmacology 24 (2): 233–40.
   PubMed Web of Science ®Google Scholar
• Bouso, J.C. 2003. MDMA/PTSD research in Spain: An update. MAPS Bulletin 13 (1): 7–8.
   Google Scholar
• Bouso, J.C.; Doblin, R.; Farre, M.; Alcazar, M.A. & Gomez-Jarabo, G. 2008. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. Journal of Psychoactive Drugs 40 (3): 225–36.
   PubMed Web of Science ®Google Scholar
• Brady, K.; Pearlstein, T.; Asnis, G.M.; Baker, D.; Rothbaum, B.; Sikes, C.R. & Farfel, G.M. 2000. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: A randomized controlled trial. JAMA 283 (14): 1837–44.
   PubMed Web of Science ®Google Scholar
• Cami, J.; Farre, M.; Mas, M.; Roset, P.N.; Poudevida, S.; Mas, A.; San, L. & de la Torre, R. 2000. Human pharmacology of 3,4-methylenedioxymethamphetamine (“ecstasy”): Psychomotor performance and subjective effects. Journal of Clinical Psychopharmacology 20 (4): 455–66.
   PubMed Web of Science ®Google Scholar
• Doblin, R. 1992. The historic FDA and NIDA meetings on hallucinogens. MAPS Bulletin 3 (3): 2–6.
   Google Scholar
• Doblin, R. 2002. A clinical plan for MDMA (ecstasy) in the treatment of posttraumatic stress disorder (PTSD): Partnering with the FDA. Journal of Psychoactive Drugs 34 (2): 185–94.
   PubMed Web of Science ®Google Scholar
• d’Otalora, M. 2004. MDMA and LSD therapy in the treatment of post traumatic stress disorder in a case of sexual abuse. Multidisciplinary Association for Psychedelic Studies. Available at: http://www.maps.org/research/mdma/moaccount.html.
   Google Scholar
• Drug Enforcement Administration. 1988. Scheduling of Controlled Substances: Scheduling of 3,4-methylenedioxymethamphetamine (MDMA) into Schedule 1 of the Controlled Substances Act: Remand. Washington, DC: Federal Register.
   Google Scholar
• Dumont, G.J.; Sweep, F.C.; van der Steen, R.; Hermsen, R.; Donders, A.R.; Touw, D.J.; van Gerven, J.M.; Buitelaar, J.K. & Verkes, R.J. 2009. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Society for Neuroscience 4 (4): 359–66.
   Google Scholar
• Freedman, R.R.; Johanson, C.E. & Tancer, M.E. 2005. Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 183 (2): 248–56.
   PubMed Web of Science ®Google Scholar
• Freudenmann, R.W.; Oxler, F. & Bernschneider-Reif, S. 2006. The origin of MDMA (ecstasy) revisited: The true story reconstructed from the original documents. Addiction 101 (9): 1241–5.
   PubMed Web of Science ®Google Scholar
• Frith, C.H.; Chang, L.W.; Lattin, D.L.; Walls, R.C.; Hamm, J. & Doblin, R. 1987. Toxicity of methylenedioxymethamphetamine (MDMA) in the dog and the rat. Fundamental and Applied Toxicology 9 (1): 110–9.
   PubMedGoogle Scholar
• Gasser, P.; Holstein, D.; Michel, Y.; Doblin, R.; Yazar-Klosinski, B.; Passie, T. & Brenneisen, R. In press. Safety and efficacy of LSD-assisted psychotherapy for anxiety associated with life-threatening diseases. Journal of Nervous and Mental Diseases.
   Google Scholar
• Gouzoulis-Mayfrank, E. & Daumann, J. 2006. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: How strong is the evidence for persistent brain damage? Addiction 101 (3): 348–61.
   PubMed Web of Science ®Google Scholar
• Greer, G.R. & Tolbert, R. 1998. A method of conducting therapeutic sessions with MDMA. Journal of Psychoactive Drugs 30 (4): 371–9.
   PubMed Web of Science ®Google Scholar
• Grob, C.S.; Poland, R.E.; Chang, L. & Ernst, T. 1996. Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: Methodological considerations and preliminary observations. Behavioural Brain Research 73 (1–2): 103–7.
   PubMed Web of Science ®Google Scholar
• Halpern, J.H.; Sherwood, A.R.; Hudson, J.I.; Gruber, S.; Kozin, D. & Pope, H.G. Jr. 2011. Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs. Addiction106 (4): 777–86.
   PubMed Web of Science ®Google Scholar
• Harris, D.S.; Baggott, M.; Mendelson, J.H.; Mendelson, J.E. & Jones, R.T. 2002. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 162 (4): 396–405.
   PubMed Web of Science ®Google Scholar
• Lester, S.J.; Baggott, M.; Welm, S.; Schiller, N.B.; Jones, R.T.; Foster, E. & Mendelson, J. 2000. Cardiovascular effects of 3,4-methylenedioxymethamphetamine: A double-blind, placebo-controlled trial. Annals of Internal Medicine 133 (12): 969–73.
   PubMed Web of Science ®Google Scholar
• Marshall, R.D.; Beebe, K.L.; Oldham, M. & Zaninelli, R. 2001. Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. American Journal of Psychiatry 158 (12): 1982–8.
   PubMed Web of Science ®Google Scholar
• Mas, M.; Farre, M.; de la Torre, R.; Roset, P.N.; Ortuno, J.; Segura, J. & Cami, J. 1999. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. Journal of Pharmacology and Experimental Therapeutics 290 (1): 136–45.
   PubMed Web of Science ®Google Scholar
• McLellan, A.T.; Kushner, H.; Metzger, D.; Peters, R.; Smith, I.; Grissom, G.; Pettinati, H. & Argeriou, M. 1992. The fifth edition of the Addiction Severity Index. Journal of Substance Abuse Treatment 9 (3): 199–213.
   PubMed Web of Science ®Google Scholar
• Metzner, R. & Adamson, S. 2001. Using MDMA in healing, psychotherapy and spiritual practice. In J. Holland (Ed.) Ecstasy, a Complete Guide: A Comprehensive Look at the Risks and Benefits of MDMA. Rochester, VT: Inner Traditions.
   Google Scholar
• Mithoefer, M.C.; Wagner, M.T.; Mithoefer, A.T.; Jerome, L. & Doblin, R. 2011. The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. Journal of Psychopharmacology 25 (4): 439–52.
   PubMed Web of Science ®Google Scholar
• Mithoefer, M.C.; Wagner, M.T.; Mithoefer, A.T.; Jerome, L.; Martin, S.F.; Yazar-Klosinski, B.; Michel, Y.; Brewerton, T.D. & Doblin, R. 2013. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: A prospective long-term follow-up study. Journal of Psychopharmacology 27 (1): 28–39.
   PubMed Web of Science ®Google Scholar
• Naranjo, C. 2001. Experience with the interpersonal psychedelics. In J. Holland (Ed.) Ecstasy, a Complete Guide: A Comprehensive Look at the Risks and Benefits of MDMA, pp. 208–21. Rochester, VT: Inner Traditions.
   Google Scholar
• Oehen, P.; Traber, R.; Widmer, V. & Schnyder, U. 2013. A randomized, controlled pilot study of MDMA (+/- 3,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). Journal of Psychopharmacology 27 (1): 40–52.
   PubMed Web of Science ®Google Scholar
• Ricaurte, G.A. 1989. Studies of MDMA-induced neurotoxicity in nonhuman primates: A basis for evaluating long-term effects in humans. NIDA Research Monographs 94: 306–22.
   PubMedGoogle Scholar
• Ricaurte, G.A.; DeLanney, L.E.; Wiener, S.G.; Irwin, I. & Langston, J.W. 1988. 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Research 474 (2): 359–63.
   PubMed Web of Science ®Google Scholar
• Ricaurte, G.A.; Martello, A.L.; Katz, J.L. & Martello, M.B. 1992. Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: Neurochemical observations. Journal of Pharmacology and Experimental Therapeutics 261 (2): 616–22.
   PubMed Web of Science ®Google Scholar
• Ricaurte, G.A. & McCann, U.D. 1992. Neurotoxic amphetamine analogues: Effects in monkeys and implications for humans. Annals of the New York Academy of Sciences 648: 371–82.
   PubMed Web of Science ®Google Scholar
• Rogers, G.; Elston, J.; Garside, R.; Roome, C.; Taylor, R.; Younger, P.; Zawada, A. & Somerville, M. 2009. The harmful health effects of recreational ecstasy: A systematic review of observational evidence. Health Technology Assessment Journal 13 (6): iii–iv, ix–xii,1–315.
   Web of Science ®Google Scholar
• Shulgin, A.R. & Shulgin, A. 1991. Pihkal: A Chemical Love Story, 1st ed. Berkeley, CA: Transform Press.
   Google Scholar
• Stolaroff, M. 2004. The Secret Chief Revealed: Conversations with a Pioneer of the Underground Therapy Movement. Sarasota, FL: Multidisciplinary Association for Psychedelic Studies.
   Google Scholar
• Weathers, F.W.; Keane, T.M. & Davidson, J.R. 2001. Clinician-administered PTSD scale: A review of the first ten years of research. Depression and Anxiety 13 (3): 132–56.
   PubMed Web of Science ®Google Scholar